초록 ▼

This invention relates to a novel transdermal drug delivery system whereby Huperzine A ("Hup A"), a naturally occurred Acetylcholine esterase inhibitor traditionally used to alleviate memory problem, is formulated for transdermal administration suitable for the treatment of Alzheimer's Disease ("AD"

This invention relates to a novel transdermal drug delivery system whereby Huperzine A ("Hup A"), a naturally occurred Acetylcholine esterase inhibitor traditionally used to alleviate memory problem, is formulated for transdermal administration suitable for the treatment of Alzheimer's Disease ("AD") to increase the efficacy and convenience for outpatient care of AD patients. A controlled-release skin patch designed for once-a-week application of Hup A is provided for easy AD medication according to the invention.

대표청구항 ▼

1. A rate-controlled transdermal drug delivery device for transdermal delivery of Huperzine A at a therapeutically effective rate in a linear square root of time manner for up to at least 7 days to provide therapeutical benefits to patients with Alzheimer's disease, comprising;(a) a concentration of

1. A rate-controlled transdermal drug delivery device for transdermal delivery of Huperzine A at a therapeutically effective rate in a linear square root of time manner for up to at least 7 days to provide therapeutical benefits to patients with Alzheimer's disease, comprising;(a) a concentration of Huperzine A in an amount sufficient to enable transdermal delivery of said Huperzine A at said therapeutically effective rate of no less than 0.833-1.46 ug/cm2.h to exhibit said therapeutical benefits; (b) a solution of adhesive polymer in a concentration sufficient to form a Huperzine A dispersing pressure-sensitive adhesive with said concentration of Huperzine A wherein said solution of adhesive polymer is adjusted to a pH range in which said concentration of Huperzine A is predominantly in a neutral form to achieve transdermal delivery of said Huperzine A at said therapeutically effective rate in said linear square root of time manner for up to at least 7 days per one administration; and (c) a sheet of drug-impermeable backing laminate added to support said Huperzine A dispersing pressure-sensitive.